Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

Video

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

While there are some broad frameworks in place for decision-making, Tripathy says, many patients do not fit easily into those frameworks. In the first-line, patients who have not been treated with trastuzumab (or were treated with trastuzumab over one year ago) should receive a combination of trastuzumab, pertuzumab, and docetaxel or another taxane. The question then remains as to how this group should be treated next, Tripathy says.

It is known that T-DM1 is superior to capecitabine and lapatinib, but again, questions remain regarding what should be done when a patient progresses in a short period of time. Tripathy says oncologists can treat based on phase II results, but there is no way to definitively know what is best for a given situation.

Related Videos
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Don S. Dizon, MD
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Reshma Lillaney Mahtani, DO
Patrick I. Borgen, MD
Henry Kuerer, MD, PhD, FACS, CMQ
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania